NCT05268692RecruitingPhase 2/3
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP
Source: ClinicalTrials.gov · Last updated 7 Mar 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 1 Feb 2022
- Start date
- 1 Jan 2019
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Kochi University
- Diseases
- Pancreatic cancer
- NCT number
- NCT05268692
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 500
- From 1 Jan 2019 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- a previous cancer surgery a body weight loss of \>10% during the 6 months before surgery the presence of distant metastases seriously impaired function of vital organs because of respiratory, renal, or heart disease.
Who the study is looking for
- elective pancreatectomy for pancreatic cancer
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Takehiro Okabayashi Coordinator of this site? Confirm its status | Kochi | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.